Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Celsion Corporation
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Number of employees : 27 people.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Oncology Drugs0.500100%0.500100% 0%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States0.500100%0.500100% 0%
Managers
NameAgeSinceTitle
Michael H. Tardugno692014Chairman, President & Chief Executive Officer
Jeffrey Wayne Church632013CFO, Secretary & SVP-Investor Relations
Nicholas Borys, Dr.602017Chief Medical Officer & Senior Vice President
Khursheed Anwer, Dr.602015Chief Scientific Officer & Executive VP
Pok Yu Chow, Dr.672007Independent Director
Robert W. Hooper732013Independent Director
Frederick J. Fritz692011Independent Director
Andreas Voss, Dr.612015Independent Director
Donald P. Braun, Dr.702015Independent Director
Stacy R. Lindborg, Dr.492021Independent Director
Members of the board
NameAgeSinceTitle
Michael H. Tardugno692014Chairman, President & Chief Executive Officer
Pok Yu Chow, Dr.672007Independent Director
Robert W. Hooper732013Independent Director
Frederick J. Fritz692011Independent Director
Andreas Voss, Dr.612015Independent Director
Donald P. Braun, Dr.702015Independent Director
Stacy R. Lindborg, Dr.492021Independent Director
Christine A. Pellizzari522021Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 86,558,070 86,090,872 99.5% 334 0.0% 99.5%
Shareholders
NameEquities%
Ayrton Capital LLC 5,555,555 6.42%
Altium Capital Management LP 3,496,154 4.04%
The Vanguard Group, Inc. 3,093,480 3.57%
FiveT Capital AG 2,750,000 3.18%
Morgan Stanley & Co. LLC 1,902,919 2.20%
Lincoln Park Capital Fund LLC 1,581,429 1.83%
BlackRock Fund Advisors 1,055,608 1.22%
Geode Capital Management LLC 514,955 0.59%
Heights Capital Management, Inc. 337,826 0.39%
GSA Capital Partners LLP 266,603 0.31%
Company contact information
Celsion Corp.
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648

Phone : +1.609.896.9100
Fax : +1.609.896.2200
Web : http://www.celsion.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Celsion Corporation
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
CELSION CORPORATION74.40%107
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628
BEIGENE, LTD.24.54%29 784
GENMAB A/S10.52%28 359
ARGENX SE10.41%16 252
HUALAN BIOLOGICAL ENGINEERING INC.-14.44%10 217
NEUROCRINE BIOSCIENCES, INC.4.87%9 504
DENALI THERAPEUTICS INC.-11.97%8 936
ARROWHEAD PHARMACEUTICALS, INC.11.61%8 914
MIRATI THERAPEUTICS, INC.-24.17%8 568
REMEGEN CO., LTD.34.63%8 070
ACCELERON PHARMA INC.0.23%7 784
ASCENDIS PHARMA A/S-15.49%7 587
FATE THERAPEUTICS, INC.-11.77%7 544
EXELIXIS, INC.11.66%7 023
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.62.63%6 504